Clinical trials: Ticagrelor
PRU, miRNA
The Relationship of Platelet Micro-RNA Expression and Platelet Reactivity in Patients Under Clopidogrel or Ticagrelor Treatment
For acute coronary syndrome patients undergoing cardiac catheterization after stenting, we will give dual antiplatelet drugs (dual antiplatelet agents) therapy, the choice of the basis of medical criteria (clinical guidelines)…
- Trial name
- NCT02101437
- Testing
- miRNA within 24hr, miRNA after 1 week, miRNA after 1 month
- Where
- Taiwan
- Volunteers
- 175 people
- Sponsor
- Taipei City Hospital
Coronary Artery Disease, Acute Coronary Syndrome
Ticagrelor Monotherapy in PAtients Treated With New-generation Drug-eluting Stents for Acute Coronary Syndrome; T-PASS Trial
We hypothesized that ticagrelor monotherapy might be enough to prevent thromboembolic events without aspirin after PCI in patients with acute coronary syndrome(ACS).
- Trial name
- NCT03797651
- Testing
- Standard DAPT, Very-short DAPT less than 1 month after PCI
- Where
- South Korea
- Volunteers
- 2,850 people
- Sponsor
- Yonsei University
Healthy
Study to Evaluate the Safety, Tolerability, PK and PD of PB2452 in Healthy Younger, Older and Elderly Subjects
This is a Phase 2A, randomized, double-blind, placebo-controlled, single dose, sequential group study to evaluate the safety, tolerability, PK, and PD of PB2452 vs matching placebo with ticagrelor (with or without acetylsalicylic…
- Trial name
- NCT03928353
- Testing
- PB2452 Infusion, Ticagrelor Oral Tablet - Pre-Treatment, Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- SFJ Pharmaceuticals, Inc.
Coronary Artery Disease
Ticagrelore Alone Post PCI
After PCI for CCS patients, single center double blind randomization will be done and patients will receive aspirin 80 mg and clopidogrel 75 mg versus 90 mg two times daily of ticagrelor, for 6 months and MACE will be followed in…
- Trial name
- TICALONE (NCT06509893)
- Testing
- aspirin 80 mg and clopidogrel 75 mg daily, Ticagrelor 90 MG
- Where
- 2 sites in Iran
- Volunteers
- 5,400 people
- Sponsor
- Shiraz University of Medical Sciences
Acute Coronary Syndrome
Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients
The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in ACS patients undergoing an Ad Hoc PCI
- Trial name
- NCT01603082
- Testing
- Ticagrelor, Clopidogrel
- Where
- 16 sites in United States
- Volunteers
- 343 people
- Sponsor
- AstraZeneca
Individualized and Combined Effects of Smoking and Diabetes on the Antiplatelet Activity in Patients Undergoing Primary Percutaneous Coronary Intervention
Individualized and Combined Effects of Diabetes and Smoking on the Antiplatelet Activity of Ticagrelor in Acute Myocardial Infarction Patients Undergoing Primary PCI
Background:Diabetes and smoking are common factors found to increase platelet reactivity in patients undergoing primary PCI. Objective: Compare the individualized and combined effects of smoking and diabetes on the antiplatelet…
- Trial name
- NCT05911659
- Testing
- Ticagrelor
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Mina Wageh Mohareb
Chronic Kidney Disease
ONSET and OFFSET of Ticagrelor in ESRD
Patients with severe chronic kidney disease or end stage renal disease (ESRD) on hemodialysis (HD) exhibited higher platelet reactivity to clopidogrel than did those with normal renal function.
- Trial name
- NCT02163954
- Testing
- Ticagrelor, Clopidogrel
- Where
- South Korea
- Volunteers
- 16 people
- Sponsor
- Kyunghee University Medical Center
ST-elevation Myocardial Infarction
Standard (180mg) Versus Double (360mg) Loading Dose of Ticagrelor in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)
This is a multi-center, prospective, randomized, single-blind, investigator initiated, pharmacodynamic study of parallel design, performed at 3 institutions (Patras University Hospital; Evangelismos Athens General Hospital…
- Trial name
- NCT01575795
- Testing
- Ticagrelor
- Where
- Greece
- Volunteers
- 83 people
- Sponsor
- University of Patras
Atherosclerosis
TIcagrelor in Rotational Atherectomy to Reduce TROPonin Enhancement
Rotational atherectomy (RA) prior to angioplasty is the reference treatment for highly calcified atherosclerotic coronary lesions.
- Trial name
- TIRATROP (NCT02505399)
- Testing
- ticagrelor, clopidogrel
- Where
- 4 sites in France
- Volunteers
- 180 people
- Sponsor
- University Hospital, Toulouse
Ischemic Preconditioning
A Trial Comparing the Ischemic Preconditioning Effects of Ticagrelor and Clopidogrel in Humans
Antiplatelet therapy remains a cornerstone in the treatment of acute and chronic coronary artery disease. Aspirin was the first such therapy to prove its benefits in acute myocardial infarction.
- Trial name
- ETCH (NCT01743937)
- Testing
- Coronary occlusion with balloon inflation
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of Texas Southwestern Medical Center
Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout
Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and Prasugrel
The purpose of the study is to describe patient characteristics and drug usage among patients that are prescribed ticagrelor for the first time and to compare them with patients who are prescribed clopidogrel and prasugrel for…
- Trial name
- NCT01276275
- Testing
- Risk of selected safety events
- Where
- Sweden
- Volunteers
- 7,200 people
- Sponsor
- AstraZeneca
Coronary Artery Disease
High Clopidogrel Dose Versus Prasugrel and Ticagrelor in High Reactive Stable Patients
Dual antiplatelet therapy with Aspirin and Clopidogrel for at least one year is essential in patients following an acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) with drug eluting stent(s) implantation.
- Trial name
- TRIPLETE RESET (NCT01543932)
- Testing
- Clopidogrel, Prasugrel, Ticagrelor
- Where
- Italy
- Volunteers
- 81 people
- Sponsor
- University of Roma La Sapienza
Coronary Artery Disease
NIRS Ticagrelor Evaluation
The Impact of Ticagrelor on Coronary Atherosclerotic Lipid Pool and Inflammation Assessed by Near-Infrared Spectroscopy study will evaluate whether ticagrelor leads to a 20% reduction in the LCBI with NIRS/IVUS suggesting…
- Trial name
- NCT02282332
- Testing
- Ticagrelor
- Volunteers
- 30 people
- Sponsor
- Medstar Health Research Institute
Coronary Artery Disease (CAD)
Impact of CYP2C19 Genotype-guided Clopidogrel and Ticagrelor Treatment on Platelet Function Test and Metabolomics Profile
Several studies have shown that pharmacodynamic (PD) response varies between patients treated with clopidogrel and that individuals with reduced response have an increased risk of recurrent ischemic events, particularly in…
- Trial name
- NCT05516784
- Testing
- Clopidogrel, Ticagrelor
- Where
- Malaysia
- Volunteers
- 80 people
- Sponsor
- Universiti Sains Malaysia
Atrial Fibrillation, Coronary Artery Disease
Safety of "Ticagrelor+ Warfarin"in Comparison With "Clopidogrel+Aspirin+Warfarin"
The aim of this study was to assess safety of antithrombotic drug ticagrelor plus oral anticoagulation adopted in persistent or permanent AF(Atrial fibrillation) patients（CHA2DS2VASc≥2） after PCI-S with specially regard to the…
- Trial name
- NCT02206815
- Testing
- Ticagrelor+Warfarin, Clopidogrel+Aspirin+Warfarin
- Where
- 3 sites in China
- Volunteers
- 296 people
- Sponsor
- Genshan Ma
Myocardial Infarction
Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor represents the standard of care for the long-term secondary prevention of atherothrombotic events in patients with myocardial infarction (MI).
- Trial name
- VORA-PRATIC (NCT02545933)
- Testing
- Prasugrel, Vorapaxar, Aspirin
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- University of Florida
Acute Coronary Syndrome, Bleeding
The Risk of Major Bleeding With Novel Anti-platelets: A Comparison of Ticagrelor With Clopidogrel in a Real World Population of 5000 Patients Treated for Acute Coronary Syndrome
A retrospective real world analysis of bleeding events with ticagrelor compared to clopidogrel in ACS patients.
- Conditions
- Acute Coronary Syndrome, Bleeding, Novel Anti-platelets, Ticagrelor
- Trial name
- ROBOT-ACS (NCT02484924)
- Testing
- Ticagrelor
- Where
- United Kingdom
- Volunteers
- 5,225 people
- Sponsor
- Liverpool University Hospitals NHS Foundation Trust
Acute Coronary Syndrome
Antithrombotic Effects of Ticagrelor Versus Clopidogrel
The purpose of this study is to determine whether treatment with ticagrelor (plus aspirin and bivalirudin) is more effective than treatment with clopidogrel (plus aspirin and bivalirudin).
- Trial name
- NCT01642238
- Testing
- Ticagrelor + ASA + Bivalirudin, Clopidogrel + ASA + Bivalirudin
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Juan J Badimon
Coronary Artery Disease
Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor
The primary objective is to determine the pharmacodynamic effect of ticagrelor dosing (180mg LD/ 90mg BID) at 2, 4 hours and 14 days in stable Coronary artery disease (CAD) patients who exhibit high-on prasugrel platelet…
- Trial name
- HEIGHTEN (NCT01869309)
- Testing
- Prasugrel, Ticagrelor
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- LifeBridge Health
Acute Coronary Syndrome
Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary Syndrome
This study proposes to conduct the switch from ticagrelor to prasugrel in an organized stepwise manner, to allow for the evaluation of the relative efficacy of prasugrel versus ticagrelor using a stepped-wedge cluster randomized…
- Trial name
- SWITCH (NCT05183178)
- Testing
- Prasugrel 10 mg p.o, Ticagrelor 90 mg
- Where
- Sweden
- Volunteers
- 17,095 people
- Sponsor
- Vastra Gotaland Region